Supriya Lifescience Chart
Supriya Lifescience Share Key Metrics
Volume
2.68 L
Market Cap
4728.77 CR
LTQ@LTP
7@587.55
ATP
588.43
Var Margin
20.25 %
Circuit Range
474.1-711.1
Delivery %
39.26 %
Value
15.74 CR
ASM/GSM
No
Market Lot
1
Summary
Supriya Lifescience Fundamentals
View MoreP/E Ratio
0
P/B Ratio
0
Div. Yield
0
Sector P/E
58.52
Sector P/B
3.11
Sec. Div. Yield
0.6
Supriya Lifescience Resistance and Support
Pivot 590.88
Resistance
First Resistance
607.66
Second Resistance
622.73
Third Resistance
639.51
Support
First Support
575.81
Second Support
559.03
Third Support
543.96
Supriya Lifescience Corporate Actions
| Date | Agenda |
|---|---|
| 2026-02-09 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
| 2025-05-27 | Audited Results & Final Dividend |
| 2025-03-10 | Others |
| 2025-01-24 | Quarterly Results & Others |
Supriya Lifescience News
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Change in Directorate
Supriya Lifescience's Independent Directors, Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain, will conclude their five-year tenure on March 24, 2026. This led to the reconstitution of the Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees.
Mar 24 2026 17:03:00
Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Supriya Lifescience published its Postal Ballot Notice for shareholder approval of key board appointments. The notice includes resolutions for two new Independent Directors and the re-appointment of one existing Independent Director, each for a five-year term.
Mar 11 2026 23:03:00
About Supriya Lifescience
NSE : 7390
BSE : 543434
ISIN : INE07RO01027
The Company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26 2008 issued by the Registrar of Companies Maharashtra at Mumbai (“RoC”) upon the conversion of ‘M/s Supriya Chemicals’ a partnership firm into a public limited company in accordance with the provisions of Part IX of the Companies Act 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approvaAwards accreditations or recognitions :2009- Certificate of Excellence for outstanding Export Performance in the product group Chemicals Drugs Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations2010- Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises Government of India2016- Export House for the Year for 2015-16 awarded by Directorate of Industries Government of Maharashtra- Export Achievement for 2015-16 in the product group Basic Chemical Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries Government of Maharashtra2017- Export House for the Year for 2016-17 awarded by Directorate of Industries Government of Maharashtra- Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries Government of Maharashtra2019- Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India
Supriya Lifescience Management
| Name | Position |
|---|---|
| Mr. Satish Waman Wagh | Chairman & Executive Director |
| Ms. Saloni Satish Wagh | Managing Director |
Supriya Lifescience Similar Stocks
Thyrocare Technologies Ltd.
361.25
-7.85 (2.13%)
Aarti Pharmalabs Ltd.
608.85
-30.15 (4.72%)
FDC Ltd.
321.10
-8.80 (2.67%)
Nephrocare Health Services Ltd.
515.50
-15.70 (2.96%)
Innova Captab Ltd.
671.35
-40.20 (5.65%)
SMS Pharmaceuticals Ltd.
386.15
-18.40 (4.55%)
Indraprastha Medical Corporation Ltd.
385.25
-19.90 (4.91%)
Senores Pharmaceuticals Ltd.
788.00
7.20 (0.92%)
Artemis Medicare Services Ltd.
215.92
-9.77 (4.33%)
Supriya Lifescience FAQs
